RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:275523

Dianzani autoimmune lymphoproliferative disease

medium confidenceDisorder

Also known as: DALD

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

24

27th percentile

Trials

0

Interventional, condition-specific

Researchers

159

Distinct authors in sample

Gene link

—

Readiness

1/6

Stages with a signal

Clinical definition (Orphanet)

Dianzani autoimmune lymphoproliferative disease (DALD) is a very rare disorder characterized by autoimmunity, lymphadenopathy and/or .

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (3)

Dianzani autoimmune lymphoproliferative syndrome · Dianzani form of autoimmune lymphoproliferative disease · autoimmune lymphoproliferative syndrome without FAS mutations

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

1/6 stages with a signal

Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    24 matched papers (9 in last 10 years) Source

  3. Phenotype characterisedNot found

    No HPO disease–phenotype associations via Monarch for these Mondo IDs

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

24

24 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

24 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

9 in the last 10 years · medium confidence · 27th percentile (publications denominator)

Phrase hits: 24 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

159

Distinct author names in 24 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Dianzani U9 papers · 2023

    Department of Health Sciences and Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), "A. Avogadro" University of Piemonte Orientale (UPO), Novara, Italy.

    Papers in Europe PMC
  2. 02
    Chiocchetti A7 papers · 2016

    Department of Health Sciences and Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), "A. Avogadro" University of Piemonte Orientale (UPO), Novara, Italy.

    Papers in Europe PMC
  3. 03
    Ramenghi U6 papers · 2014
    Papers in Europe PMC
  4. 04
    Boggio E5 papers · 2023

    Department of Health Sciences and Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), "A. Avogadro" University of Piemonte Orientale (UPO), Novara, Italy.

    Papers in Europe PMC
  5. 05
    Cappellano G4 papers · 2016

    Biocenter, Division for Experimental Pathophysiology and Immunology, Laboratory of Autoimmunity, Medical University of Innsbruck, Innsbruck, Austria.

    Papers in Europe PMC
  6. 06
    Clemente N4 papers · 2016

    Department of Health Sciences and Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), "A. Avogadro" University of Piemonte Orientale (UPO), Novara, Italy.

    Papers in Europe PMC
  7. 07
    Orilieri E4 papers · 2014
    Papers in Europe PMC
  8. 08
    Comi C3 papers · 2016

    Department of Translational Medicine, Neurology Unit, "A. Avogadro" UPO, Novara, Italy.

    Papers in Europe PMC
  9. 09
    Dianzani I3 papers · 2013
    Papers in Europe PMC
  10. 10
    Soluri MF3 papers · 2016

    Department of Health Sciences and Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), "A. Avogadro" University of Piemonte Orientale (UPO), Novara, Italy.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

medium confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Dianzani autoimmune lymphoproliferative disease — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Dianzani autoimmune lymphoproliferative disease" OR "Dianzani autoimmune lymphoproliferative syndrome" OR "Dianzani form of autoimmune lymphoproliferative disease" OR "Dianzani form of the autoimmune lymphoproliferative disease" OR "autoimmune lymphoproliferative syndrome without FAS mutations"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Dianzani autoimmune lymphoproliferative syndrome

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Dianzani autoimmune lymphoproliferative disease" OR "Dianzani autoimmune lymphoproliferative syndrome" OR "Dianzani form of autoimmune lymphoproliferative disease" OR "Dianzani form of the autoimmune lymphoproliferative disease" OR "autoimmune lymphoproliferative syndrome without FAS mutations"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: DALD

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T11:36:28.372Z